Amneal Pharmaceuticals, Inc. (AMRX) Stock
AMRX has an Alpha Score of 54 out of 100 (weak), computed on Nov 3, 2026 from 3 of 4 sub-scores. 1 member of Congress disclosed 1 trade in AMRX since 2019: 0 purchases and 1 sale, most recently Gilbert Cisneros (sale, May 29, 2019). 4 of the hedge funds AlphaScala tracks reported AMRX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $19.36M. Company insiders reported 0 open-market buys and 3 sales on SEC Form 4 in the 90 days to Nov 9, 2026. Its trailing P/E ratio is 42.7 and its net margin 5.1% (key statistics as of Oct 27, 2026).
What is AMRX's Alpha Score?
How it works →Alpha Score of 54 reflects moderate overall profile with strong momentum, poor value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 3, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Amneal Pharmaceuticals, Inc. (AMRX)?
Most recent: Gilbert Cisneros (sale, May 29, 2019); records start May 29, 2019.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2019-05-29 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 6, 2026.
See all AMRX political trades →Which hedge funds own AMRX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 1.12M | $19.36M | +94% |
| D.E. Shaw David Shaw | 774K | $13.40M | -55% |
| Renaissance Technologies Jim Simons (founder) | 87K | $1.51M | -68% |
| Millennium Management Israel Englander | 15K | $255.5K | -96% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Amneal Pharmaceuticals, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 13, 26 | Kiely John | Director | SELL | 50.0K | $882K |
| Aug 12, 26 | Daly Jason B. | EVP, Chief Legal Officer | SELL | 210.0K | $3.7M |
| Aug 12, 26 | Shah Nikita | Executive Vice President | SELL | 146.4K | $2.6M |
| Aug 11, 26 | Daly Jason B. | EVP, Chief Legal Officer | SELL | 6.6K | $117K |
SEC Form 4 filings as of Nov 9, 2026
See cluster-buy signals across all tickers →What are AMRX's key statistics?
Key statistics as of Oct 27, 2026
How does AMRX's valuation compare with the Healthcare sector?
| Metric | AMRX | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 42.7 | 29.7 | 114 |
| Net margin | 5.05% | 3.62% | 174 |
| Return on equity | 174.61% | 2.96% | 200 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 10, 2026). P/E excludes loss-making companies.
AMRX price chart
Powered by TradingViewWhat does Amneal Pharmaceuticals, Inc. do?
Amneal Pharmaceuticals Inc. is a global biopharmaceutical company that develops, manufactures, and distributes a diverse portfolio of essential medicines across three reportable segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers a broad range of generic pharmaceuticals in various dosage forms and delivery systems, including complex injectables, biosimilars like denosumab referencing Prolia and XGEVA, respiratory therapies such as albuterol sulfate inhalation aerosol equivalent to PROAIR HFA, ophthalmic products like cyclosporine emulsion equivalent to RESTASIS, and iohexol injection as the first generic of Omnipaque. The Specialty segment focuses on proprietary branded pharmaceuticals targeting central nervous system disorders, such as CREXONT for Parkinson’s disease to improve motor symptom control, and endocrine therapies like UNITHROID. The AvKARE segment supplies pharmaceuticals and medical products to governmental agencies through re-packaging and wholesale distribution, emphasizing consistent care and pricing. Operating in the U.S., India, and Ireland, Amneal Pharmaceuticals Inc. supports healthcare providers, institutions, and patients with affordable and innovative treatments. Founded in 2002 and headquartered in Bridgewater, New Jersey, it plays a key role in the generics, specialty, and institutional pharmaceuticals markets.